Researchers identified a key receptor that primes the formation of autoreactive B cells. Disrupting this pathway may be a ...
In vitro studies have suggested that BTKi therapy can suppress NOTCH1 activation via B-cell receptor–NOTCH1 interactions, providing a mechanistic rationale for these clinical results.
Early immune activation marks the onset of rheumatoid arthritis, revealing potential for early intervention and improved ...
The combination of glofitamab (Columvi) plus polatzumab vedotin (Polivy) demonstrated high efficacy and durable responses in patients with relapsed/refractory large B-cell lymphoma (LBCL), according ...
Data presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, ...
Nurix Therapeutics (NRIX) announced the presentation of new translational data from its ongoing Phase 1 study of NX-1607, an oral, first-in-class ...
The poster, titled Translational Insights from a First-in-Human Study of an Oral CBL-B Inhibitor in Advanced Solid Tumors, expands upon data presented at the recent European Society for Medical ...
A phase 1 trial reveals that combining radiotherapy with immunotherapy enhances response rates in B-cell lymphomas while maintaining manageable safety profiles.
This work reveals metabolic pathways and molecular events mechanistically linked to B cell activation. Using an unbiased, comprehensive proteome profiling method and various functional validation ...
Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, public reviews, and a provisional response from the authors. The work presented by ...
We integrated data from five prospective studies of frontline anthracycline-based chemotherapy in patients with LBCL. Tumor-specific phased variants were identified from pretreatment samples and ...
Previously FDA-approved BTK inhibitors for B-cell malignancies include ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib for CLL/SLL and acalabrutinib, zanubrutinib, and pirtobrutinib for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback